Besides other mutations, such as those of NRAS, p53 and PTEN, activating BRAF mutations are most frequently (50–60%) found in malignant melanomas [2,3,4], leading to the constitutively activation of RAF-MEK-MAPK signaling, which leads to increased cell proliferation and melanoma progression [2,5]. This evidence concerns the gene PTEN and melanoma.